Health care has a distinct place in the B20 USA Leaders’ Statement, the policy document the U.S. Chamber of Commerce has published ahead of the B20 USA Summit in Washington, November 9 to 11, 2026. Under its Innovation Task Force, the statement asks G20 governments to reduce the time between marketing authorization and patient access for new medical solutions and technologies by 30% by 2030.
For pharmaceutical, medical device and health technology companies, the recommendations address the steps that sit between regulatory approval and revenue: duplicative national reviews, fragmented health data systems and slow coverage decisions.
Four recommendations
The health priority, labeled I3 in the statement, has four parts. The first asks governments to explore harmonization of safety approvals so that proven solutions can be deployed faster. The second calls for a unified set of standards and guidelines for electronic health record systems within each country. The third asks governments to use reimbursement pathways to reduce unnecessary coverage delays for innovative products. The fourth calls for a transparent global understanding of how AI is used, both to improve access to care and to support AI-based research.
The statement supports the AI item with a data point: it reports that a subset of AI-designed drug candidates has shown Phase I success rates of 80% to 90%, compared with a historical range of 40% to 65%. The statement presents this as evidence that regulators need the capacity to assess AI-generated research.
Where it sits in the B20 process
The Innovation Task Force is chaired by David Zapolsky, Chief Global Affairs and Legal Officer of Amazon. Its other priorities cover long-term research and development incentives, trust in digital innovation and industrial technology. The Leaders’ Statement was prepared with the Boston Consulting Group as knowledge partner, and the Chamber describes it as a foundation for conversations and action at the Washington summit and beyond. The G20 Leaders’ Summit follows at Trump National Doral in Miami on December 14 and 15.
Health is not one of the four working groups of the U.S. G20 presidency, which are growth and deregulation, innovation, energy abundance and trade. The B20 recommendations on health therefore come from the business side rather than from a dedicated government track. The closest government-level link is the innovation working group, which covers standards, supply chains and skilled workforces for emerging technologies.
What business should watch
The practical questions for companies are whether governments take up harmonized approvals, so that one regulator’s review can speed another’s, and whether any G20 outcome text refers to health data standards or AI in research. Public affairs teams in the life sciences sector may want to track how health appears in the B20 plenary sessions on November 10 and 11 and in the outcome of the Leaders’ Summit in December.















